Item 16. FORM 10-K SUMMARY

2K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	BIO-TECHNE CORPORATION

Date: August 22, 2025		/s/ Kim Kelderman
			By:	Kim Kelderman
			Its:	President and CEO

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.


Date		Signature and Title

August 22, 2025		/s/ Robert V. Baumgartner
		Robert V. Baumgartner
		Chairman of the Board and Director

August 22, 2025		/s/ Julie Bushman
		Julie Bushman, Director

August 22, 2025		/s/ Rupert Vessey
		Dr. Rupert Vessey, Director

August 22, 2025		/s/ Joseph Keegan, Ph.D.
		Dr. Joseph Keegan, Director

August 22, 2025		/s/ John L. Higgins
		John L. Higgins, Director

August 22, 2025		/s/ Roeland Nusse, Ph.D.
		Dr. Roeland Nusse, Director

August 22, 2025		/s/ Alpna Seth, Ph.D.
		Dr. Alpna Seth, Director

August 22, 2025		/s/ Judith Klimovsky, M.D.
		Dr. Judith Klimovsky, Director

August 22, 2025		/s/ Amy E. Herr, Ph.D.
		Dr. Amy E. Herr, Director

August 22, 2025		/s/ Kim Kelderman
		Kim Kelderman, Director and Chief Executive Officer (principal executive officer)

August 22, 2025		/s/ James Hippel
		James Hippel, Chief Financial Officer
		(principal financial officer and principal accounting officer)

Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES